Sagimet Biosciences (SGMT) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 12, 2026, with voting available online, by mail, or by phone.

• Stockholders will vote on the election of four Class III directors for three-year terms and the ratification of KPMG as the independent auditor for 2026.

• The board consists of eight members, with a majority being independent, and is divided into three classes with staggered terms.

• Recent highlights include positive clinical trial results, regulatory progress in China, and a new at-the-market equity offering.

Voting matters and shareholder proposals

• Proposal 1: Election of Jennifer Jarrett, Anne Phillips, M.D., David Happel, and George Kemble, Ph.D. as Class III directors for terms expiring in 2029.

• Proposal 2: Ratification of KPMG LLP as the independent registered public accounting firm for 2026.

• Board recommends voting FOR all nominees and FOR the auditor ratification.

• Stockholders may submit proposals for the 2027 meeting by December 22, 2026.

Board of directors and corporate governance

• Board has eight members, six of whom are independent; leadership roles are separated between CEO and Chairman.

• Committees include Audit, Compensation, and Nominating & Corporate Governance, all composed of independent directors.

• Annual board and committee self-evaluations are conducted.

• Board diversity in background, gender, and skills is emphasized.

• Stockholder engagement is ongoing, with multiple communication channels.